Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Perhexiline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT2 known ✓ | P23786 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | MITF | O75030 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 1.00 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | TSHR | P16473 | 1/20 | 0.75 |
| ▸ | MLNR | O43193 | 1/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Perhexiline SCHEMBL123149 | 1.00 | MEN1 (1.00) | MEN1LMNATP53KMT2AHTT | |
| Perhexiline SCHEMBL28785930 | 0.98 | KMT2A (0.97) | MEN1LMNATP53KMT2AHTT | |
| Perhexiline SCHEMBL27800434 | 0.97 | KMT2A (0.94) | MEN1LMNATP53KMT2AHTT | |
| Perhexiline SCHEMBL11451421 | 0.87 | LMNA (0.80) | MEN1LMNATP53KMT2AHTT | |
| Perhexiline SCHEMBL114894 | 0.87 | CYP2D6 (1.00) | MEN1LMNATP53KMT2AHTT | |
| Perhexiline SCHEMBL145849 | 0.87 | CYP2D6 (1.00) | MEN1LMNATP53KMT2AHTT | |
| Perhexiline SCHEMBL15516137 | 0.87 | CYP2D6 (1.00) | MEN1LMNATP53KMT2AHTT | |
| Perhexiline SCHEMBL13417497 | 0.87 | CYP2D6 (1.00) | MEN1LMNATP53KMT2AHTT | |
| Perhexiline SCHEMBL28885519 | 0.85 | CYP2D6 (0.96) | MEN1LMNATP53KMT2AHTT | |
| Perhexiline SCHEMBL29089418 | 0.85 | CYP2D6 (0.96) | MEN1LMNATP53KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1069 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3749682-B1 | TREATING HETEROTOPIC OSSIFICATION | ACCELERON PHARMA INC (US) | 2025-09-24 | — | — | EP | claimed |
| US-12364736-B2 | Methods for treating heterotopic ossification | ACCELERON PHARMA INC. (US) | 2025-07-22 | — | — | US | claimed |
| WO-2025076280-A1 | METHODS AND COMPOSITIONS FOR TREATING MMP-9 MEDIATED DISORDERS | ASHIBIO, INC. (US) | 2025-04-10 | — | — | WO | claimed |
| US-20250011719-A1 | NEW METHOD FOR IMPROVING QUALITY OF PLATELETS | SHANGHAI SYNVIDA BIOTECHNOLOGY CO. LTD. (CN) | 2025-01-09 | — | — | US | claimed |
| EP-4434341-A1 | NEW METHOD FOR IMPROVING QUALITY OF PLATELETS | SHANGHAI SYNVIDA BIOTECHNOLOGY CO. LTD. (CN) | 2024-09-25 | — | — | EP | claimed |
| CN-118436782-A | Application of inhibitor of targeted fatty acid oxidation pathway in liver cancer resistance | 桂林医学院附属医院 | 2024-08-06 | — | — | CN | claimed |
| WO-2024102612-A1 | COMPOUNDS AND METHODS FOR IDENTIFYING COMPOUNDS FOR MODULATING GLUCOSE TRANSPORT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-16 | — | — | WO | claimed |
| CN-116622514-B | Regulation and control method for improving polyunsaturated fatty acid content in microbial thalli and/or microbial grease and application thereof | 南京师范大学 | 2023-10-20 | — | — | CN | claimed |
| WO-2023182736-A1 | MULTI-LAYERED TABLET COMPOSITE FORMULATION AND PREPARATION METHOD THEREFOR | 주식회사 위바이오트리 | 2023-09-28 | — | — | WO | claimed |
| CN-116622514-A | Regulation and control method for improving polyunsaturated fatty acid content in microbial thalli and/or microbial grease and application thereof | 南京师范大学 | 2023-08-22 | — | — | CN | claimed |
| CN-1582168-A | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORP (US) | 2005-02-16 | — | — | CN | claimed |
| CN-1546026-A | Dripping pills of perhexiline maleate and its preparation | 南昌弘益科技有限公司 | 2004-11-17 | — | — | CN | claimed |
| EP-1385548-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | Schering Corporation (US) | 2004-02-04 | — | — | EP | claimed |
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORPORATION | 2003-04-10 | — | — | US | claimed |
| WO-2002058731-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| US-5589395-A | BRINGING BIOLOGICAL FLUID SAMPLE INTO CONTACT WITH AGENT CONTAINING ANTICOAGULANT, CHELATE-FORMING AGENT AND AGGREGATION-INHIBITING SUBSTANCE FROM LIST SPECIFIED | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1996-12-31 | — | — | US | claimed |
| US-5464633-A | Core containing active substance to be released in gastric or intestinal tract, polymer which swells and/or gels and/or erodes on contact with water, and adjuvants and excipients; layer applied to core by compression process | JAGOTEC AG (CH) | 1995-11-07 | — | — | US | claimed |
| EP-0433927-B1 | Substance to improve the recovery of annexins | BEHRINGWERKE AG (DE) | 1995-09-20 | — | — | EP | claimed |
| US-4191828-A | CATALYTIC HYDROGENATION OF 2-(2,2-DIPHENYLETHYL)PYRIDINE | RICHARDSON-MERRELL INC. (US) | 1980-03-04 | — | — | US | claimed |
| US-4069222-A | CATALYTIC HYDROGENATION OF CORRESPONDING PYRIDINE COMPOUND, RANEY NICKEL CATALYST | RICHARDSON-MERRELL INC. (US) | 1978-01-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12364736-B2 | Methods for treating heterotopic ossification | SOST, BMP2, BMP4 | CPT2 3776/4885MEN1 1741/4885LMNA 1817/4885 |
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | CYP46A1, FABP2, SREBF1 | CPT2 200/4885MEN1 1502/4885LMNA 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.